Journal of travel medicine
-
Review
From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.
Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites. ⋯ VLA1553 is the first vaccine approved for the prevention of chikungunya disease in adults, following accelerated development based on a serological surrogate marker of protection. VLA1553 adds to strategies to reduce the spread and burden of chikungunya in endemic populations and travellers.
-
Randomized Controlled Trial
Assessing Wolbachia-mediated Sterility for Dengue Control: Emulation of a Cluster Randomized Target Trial in Singapore.
Matings between male Aedes aegypti mosquitoes infected with wAlbB strain of Wolbachia and wildtype females yield non-viable eggs. We evaluated the efficacy of releasing wAlbB-infected Ae. aegypti male mosquitoes to suppress dengue. ⋯ Results demonstrated that Wolbachia-mediated sterility can strengthen dengue control in tropical cities, where dengue burden is the greatest.
-
We present a case of coinfection with dengue and parainfluenza viruses, a coinfection that has not been described in the literature to date. This case emphasizes that fever after travel is not always caused by a single disease. Appropriate research on fever sources and infection control measures should be implemented.
-
Imported cases of Oropouche fever were recently detected in Italy. Upcoming mass events, i.e. the 2024 Olympic Games in Paris and the 2025 Jubilee in Rome, represent increasing likelihood of further OROV importation and potential spread in new areas, underscoring the importance of strengthening surveillance, laboratory capacity and ecology studies.